Abstract: The present invention provides a lipid nanoparticle used for delivering a nucleic acid to a brain tissue, including an ionic lipid represented by the formula (1), phospholipid, cholesterol, and a dimyristoylglycerol PEG with a number average molecular weight of PEG chain of 4,000 to 6,000, wherein an amount of the dimyristoylglycerol PEG is 1 to 6 mol % with respect to the total of the ionic lipid represented by the formula (1), the phospholipid, and the cholesterol (the symbols in the formula (1) are as defined in the specification).

Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Abstract: The invention provides a cationic lipid, a lipid membrane structure containing same, and use thereof. The cationic lipid is represented by the formula (1) wherein R1a, R1b, R2a, R2b, R3a, R3b, Xa, Xb, Ya, Yb, Za, and Zb are as defined in the specification.

Abstract: The present invention relates to a method for improving proliferative property of a CMP or a myeloid progenitor cell, including a step of forcibly expressing a MYC family gene and BMI1 gene in any cell in the process of differentiation from a hematopoietic progenitor cell into a myeloid progenitor cell, wherein the myeloid progenitor cell is a progenitor cell of macrophage, dendritic cell, granulocyte, erythroblast, or erythrocyte.

Abstract: The present invention is to provide an antisense oligomer or a pharmaceutically acceptable salt thereof capable of treating Werner syndrome without direct repair of a mutated gene. The present invention provides an antisense oligomer or a pharmaceutically acceptable salt thereof which consists of a base sequence complementary to the base sequence of the following (i) or (ii): (i) a contiguous base sequence of 15 or more bases in the base sequence shown in SEQ ID NO: 1; or (ii) a contiguous base sequence of 15 or more bases in the base sequence shown in SEQ ID NO: 1, having deletion, substitution, or insertion of one or more bases; and which is capable of causing skipping of the 27th exon in a human WRN gene.

Abstract: The invention provides a cationic lipid, a lipid membrane structure containing same, and use thereof. The cationic lipid is represented by the formula (1) wherein R1a, R1b, R2a, R2b, R3a, R3b, Xa, Xb, Ya, Yb, Za, and Zb are as defined in the specification.

Abstract: This preventive or therapeutic agent for inflammatory diseases or bone diseases, and this pharmaceutical composition for preventing or treating inflammatory diseases or bone diseases include, as effective components, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. [In formula (1), X is a hydrogen atom, a halogen atom, or a C1-C10 alkyl group that may be substituted; R1 is a C1-C10 alkyl group that may be substituted, a C1-C10 alkenyl group that may be substituted, or a C6-C14 aryl group that may be substituted; and one or more hydrogen atoms may be substituted with deuterium atoms.

Abstract: An object of the invention is to provide a comprehensive biomarker for artery lesions, and diabetes mellitus, heart disease, cerebrovascular disorder, cancer, kidney disease, etc., whose onset and progress can be suppressed by health care such as early diagnosis. The inventors have found that the object can be attained by determining the level of an antibody to protein KIAA0513 or a portion of the protein, the antibody being potentially present in a body fluid sample collected from a living body; and acquiring data showing a rise in the antibody level as data showing the presence of an artery lesion or the potential or actual presence of cerebrovascular or cardiovascular disorder, diabetes mellitus, chronic kidney disease, or a solid cancer.

Abstract: To provide an electrode for an electricity storage device, which electrode employs a porous conductor having conductive nanostructures formed on its surface and makes it possible to provide a less expensive electricity storage device having a high discharge capacity and high charge/discharge cycle resistance. A porous conductor which is used as an electrode for an electricity storage device has a plurality of conductive nanostructures on a surface of the porous conductor.

Abstract: The invention tracks and automatically evaluates plant traits of “individuals of plant canopy” in a growth process of a germination period (from sowing until immediately prior to primary seedling culture), at a plant factory with artificial lighting. Specifically, a two-dimensional distribution of the plant traits is calculated by non-destructively and continuously measuring plant trait information in the growth process of the germination period, on the basis of image information 2a, environmental factor information 2b, genetic characteristic information 2c, and management information 2d.

Abstract: A biological state monitoring system (100) for monitoring a biological state of a subject on a bed (BD) over a predetermined monitoring period, includes: at least one load detector (11, 12, 13, 14) configured to detect a load of the subject on the bed; and a respiratory rate estimating unit (34) configured to successively obtain and output estimated values of a respiratory rate of the subject, based on a temporal variation of a detection value of the load detector. The monitoring period includes a body motion period in which the subject has a body motion, and a resting period in which the subject merely performs a respiration.

Abstract: A method for detecting anti-deoxyhypusine synthase autoantibody in a subject, wherein the method includes detecting, in a blood, serum, or plasma sample from a test subject with digestive system cancer, the amount of anti-deoxyhypusine synthase autoantibody, wherein the autoantibody is able to bind to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

Abstract: A sightline-position determination device includes: a sightline-position input unit to which a position of a sightline of a user is inputted; a determination region setting unit which sets a determination region; a determination unit which determines whether or not the position of the sightline inputted from the sightline-position input unit falls within the determination region; and an output unit which outputs feedback to the user when the determination unit has determined that the position of the sightline falls within the determination region.

Abstract: An object of the present invention is to provide an external pharmaceutical composition that imparts light stability to a ?-blocker (particularly propranolol hydrochloride) and is excellent in the balance between transdermal absorbability and skin retention, and the present invention provides a complex composed of a water-soluble ?-blocker and lecithin, a method for producing the complex, an external pharmaceutical composition containing the complex, and the like. The complex or a dispersion in oil containing the complex is applied to an existing pharmaceutical external preparation formulation (for example, W/O type cream), and a complex containing a ?-blocker is allowed to be present in the O phase, thereby avoiding contact with water or dissolved oxygen and reducing the risk of photolysis.

Abstract: The present invention provides an antibody or a fragment thereof, which specifically binds to a 6-sulfosialyl Lewis X glycan, where the binding requires fucose, a sulfate group, and a sialic acid that form the 6-sulfosialyl Lewis X glycan.

Abstract: An allergic disease determination method includes contacting probes selected from an allergen and a fragment thereof and a biological sample collected from a subject; detecting a reaction between the probes and an antibody contained in the biological sample; determining a type of the antibody reacted with the probes; inputting data associated with the reaction of each of the at least two types of probes with the antibody and data associated with a type of the bound antibody into a prediction model and acquiring a prediction result; and determining an allergic disease on the basis of the prediction result. The prediction model is a nonlinear model or a model having two or more explanatory variables and two or more terms, the model being created using training data associated with the reaction of at least the probes with the antibody and training data associated with the type of the bound antibody.

Abstract: A determination device includes an acquisition unit, a first determination unit, a second determination unit, and an output unit. The acquisition unit is configured to acquire a sightline direction of a user and a sightline direction of at least one facing person facing the user. The first determination unit is configured to determine whether a sightline of the user is directed to the facing person based on the sightline direction of the user acquired by the acquisition unit. The second determination unit is configured to determine whether a sightline of the facing person is directed to the user based on the sightline direction of the facing person acquired by the acquisition unit. The output unit is configured to output a feedback to the user and/or an executor based on a result of a determination of the first determination unit and a result of a determination of the second determination unit.

Abstract: The present inventors have surprisingly found that a deoxyhypusine synthase (DHPS) gene, which was previously reported to correlate with prostate cancer and cervical cancer, is highly responsive to arteriosclerosis or digestive system cancer, whereby the gene can be used as a desired marker for arteriosclerosis or digestive system cancer. The present invention has been accomplished on the basis of this finding. Specifically, the present invention provides a method for determining arteriosclerosis or digestive system cancer, which method includes detecting expression of a deoxyhypusine synthase gene in a test sample (preferably a blood sample), and determining arteriosclerosis or digestive system cancer of a test subject from which the test sample has been obtained, on the basis of an increase in the gene expression as an index.

Abstract: A liquid composition includes a thiophene polymer; and at least one polymerization component selected from the group including a monomer and an oligomer.

Abstract: A composition for forming a metallic luster film, includes: a thiophene polymer, in which a total content of an Fe atom, a Cu atom, an Mn atom, a Cr atom, and a Ce atom in the composition for forming a metallic luster film is 1500 ppm or less with respect to the thiophene polymer.